Navigation Links
Exonuclease III from Promega
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... Sac-Cel (Second Antibody Coated CELlulose) was ... Diagnostics of Dartford, Kent, one of the ... world. IDS acquired the product range in ... and clinical biochemists developing their own "in ...
... standard is a new tuning and calibration ... mass spectrometry. Accumix is a lyophilized ... coverage for both tuning and calibration of ... and Fourier transform mass spectrometers. Direct ...
Determin interaction of your protein with Echelons lipids...
Biology Products:
(Date:12/16/2009)... -- BIO-key International, Inc. (OTC Bulletin Board: ... and finger-based biometric identification solutions, announced that ... Special Shareholder Meeting held today approved the ... to Interact911 Mobile Systems Inc. Of the ... and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... -- CSC (NYSE: CSC ) ... Laboratory Accreditation awarded the International Organization for ... the company,s Test Lab, which is part ... Fairmont, W.Va. The Test Lab is the ... to achieve this accomplishment. ,, (Logo: ...
(Date:12/15/2009)... diseases such as Alzheimer,s and Parkinson,s, doctors can reach ... a patient. , But they come up empty-handed when ... with ataxia disabling disorders that rob people of ... are trying to change that with the help of ... of Neurological Disorders and Stroke to establish a nationwide ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 1New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 2New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 3New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 4New Families and Work Institute Study Reveals Declines in the Health of American Workforce 57900 5Sirion Therapeutics Announces FDA Approval of Zirgan 28TM 29 28Ganciclovir Ophthalmic Gel 29 0 15 25 for Herpetic Keratitis 57895 1Sirion Therapeutics Announces FDA Approval of Zirgan 28TM 29 28Ganciclovir Ophthalmic Gel 29 0 15 25 for Herpetic Keratitis 57895 2Sirion Therapeutics Announces FDA Approval of Zirgan 28TM 29 28Ganciclovir Ophthalmic Gel 29 0 15 25 for Herpetic Keratitis 57895 3Sirion Therapeutics Announces FDA Approval of Zirgan 28TM 29 28Ganciclovir Ophthalmic Gel 29 0 15 25 for Herpetic Keratitis 57895 4Advanced Analogic Technologies Introduces Lowest Power Load Switch Available for Biometric Security Devices 10022 1Advanced Analogic Technologies Introduces Lowest Power Load Switch Available for Biometric Security Devices 10022 2Advanced Analogic Technologies Introduces Lowest Power Load Switch Available for Biometric Security Devices 10022 3
... as key to Komodo Dragon,s hunting strategy. , A ... Komodo Dragon bite is a combination of highly specialized ... widely accepted theory that prey die from septicemia caused ... Using sophisticated medical imaging techniques, an international team led ...
... the palm of your hand can never give accurate results. Whether ... job interview, you,re better off asking a trusted friend if your ... you need one? , Tel Aviv University researchers have come ... lets you know if malodorous bacteria are brewing in your mouth. ...
... By creating a model of the active site found ... Illinois have described a catalyst that acts like nature,s most ... a paper accepted for publication in the Journal of ... Web site. , Scientists have long been puzzled by nature,s ...
Other Biology News:A combined tooth-venom arsenal revealed as key to Komodo dragon's hunting strategy 2Are you okay to kiss? 2Are you okay to kiss? 3
(Date:12/16/2009)... Trial conducted pursuant to Special Protocol Assessment ... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna ... AEZ) (the "Company"), a global biopharmaceutical company ... announced the initiation, by its partner Keryx ... Phase 3 registration clinical trial for perifosine ...
(Date:12/16/2009)... has been found to be effectinve in improving yelds of probiotic ... ... BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting the demand for Non-Animal ... Nutricepts, Inc. (Burnsville, Mn), is a high quality Soy Peptone. ... has been found to be especially effective in improving yields of ...
(Date:12/15/2009)... Joint BioEnergy Institute (JBEI), one of three Department of ... trusted time-stamping service to protect its valuable intellectual property. ... ... VA (PRWEB) December 15, 2009 -- Surety, LLC ... solutions , today announced that the Joint BioEnergy Institute ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, The Future of Orphan ... Pipeline Analysis and Reimbursement ,, ... Summary ,, The author has ... Orphan Diseases Therapeutics - Market Forecasts to ...
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18